This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of accessory sinuses, excluding all cancers (controls excluding all cancers)
C3_ACCESSORY_SINUS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
165 |
4. Check minimum number of eventsNone |
165 |
5. Include endpointsNone |
165 |
6. Filter based on genotype QC (FinnGen only) |
165 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of accessory sinuses, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of nasal cavity and sinuses, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of respiratory system and intrathoracic organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 165 | 60 | 105 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | 63.51 | 60.63 | 65.15 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 76
- Matched controls
- 758
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
130
Kela drug reimbursment
Malignant tumour
+∞
38.9
34
*
C31.0
ICD-10 Finland
Malignant neoplasm: Maxillary sinus
+∞
30.2
27
*
WF002
NOMESCO Finland
Radical radiotherapy
+∞
25.4
23
*
H02AB02
ATC
dexamethasone; systemic
285.0
21.8
21
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
20.8
19
*
8070/3-C31.0
ICD-O-3
Squamous cell carcinoma, NOS, of maxillary sinus
+∞
19.6
18
*
A03FA01
ATC
metoclopramide; systemic, rectal
14.1
18.5
34
41
C30.0
ICD-10 Finland
Malignant neoplasm: Nasal cavity
+∞
18.5
17
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
18.5
17
*
DHA10
NOMESCO Finland
Biopsy of cavity of nose
215.4
17.2
17
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
16.2
15
*
D38.51
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of other accessory sinus
+∞
16.2
15
*
C31.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of accessory sinuses
+∞
16.2
15
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
16.2
15
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
17.3
16.2
26
22
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
8.7
15.7
41
90
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
15.1
14
*
D14.0
ICD-10 Finland
Benign neoplasm: Middle ear, nasal cavity and accessory sinuses
183.9
15.0
15
*
N02AA05
ATC
oxycodone; systemic
11.7
14.3
28
36
UDM02
NOMESCO Finland
Sinoscopy
43.0
14.2
17
5
A04AA01
ATC
ondansetron; systemic, rectal
61.3
13.4
15
*
XX3DW
NOMESCO Finland
Time consuming IT work
22.5
13.4
19
11
DM1DG
NOMESCO Finland
Paranasal sinuses and face area very extensive MRI examination with high intensity magnet
+∞
12.9
12
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
11.8
11
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
11.8
11
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
51.5
11.3
13
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
51.5
11.3
13
*
DNB20
NOMESCO Finland
Endoscopic ethmoidectomy
51.5
11.3
13
*
JN4BD
NOMESCO Finland
Extensive body CT
22.0
11.3
16
9
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
38.6
10.7
13
*
DM1BD
NOMESCO Finland
Extensive CT of paranasal sinuses and face area
126.8
10.7
11
*
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
10.7
10
*
L03AA02
ATC
filgrastim; parenteral
+∞
10.7
10
*
Z51.5
ICD-10 Finland
Palliative care
24.1
10.2
14
7
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
12.5
9.6
17
17
EEB00
NOMESCO Finland
Partial excision of maxilla
+∞
9.6
9
*
C31.9
ICD-10 Finland
Malignant neoplasm: Accessory sinus, unspecified
+∞
9.6
9
*
DMA00
NOMESCO Finland
Biopsy of maxillary antrum
+∞
9.6
9
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
+∞
9.6
9
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
9.6
9
*
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
56.8
8.9
10
*
DCA20
NOMESCO Finland
Insertion of ventilating tube through tympanic membrane
100.8
8.6
9
*
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
17.1
8.6
13
9
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
8.5
8
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
8.5
8
*
ZZQ00
NOMESCO Finland
Free microvascular graft of skin
+∞
8.5
8
*
C31.1
ICD-10 Finland
Malignant neoplasm: Ethmoidal sinus
+∞
8.5
8
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
+∞
8.5
8
*
L03AA13
ATC
pegfilgrastim; parenteral
+∞
8.5
8
*
EEB10
NOMESCO Finland
Maxillectomy
+∞
8.5
8
*
D38.50
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of maxillary sinus
+∞
8.5
8
*
A04AD12
ATC
aprepitant; systemic
+∞
8.5
8
*
PJD81
NOMESCO Finland
Excision of lymph nodes from upper part of neck
+∞
8.5
8
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
8.5
8
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
7.6
8.4
20
34
WW500
NOMESCO Finland
Blood transfusion
20.0
8.4
12
7
SAA03
NOMESCO Finland
Extended examination of mouth
4.3
8.3
40
155
EP1AE
NOMESCO Finland
Neck ultrasound examination
17.5
8.0
12
8
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
28.4
7.8
10
*
ZXC95
NOMESCO Finland
Use of surgical navigator
88.4
7.6
8
*
AAE99
NOMESCO Finland
Other operation by cranial base approach
+∞
7.4
7
*
DM1CG
NOMESCO Finland
Paranasal sinuses and face area extensive MRI examination with high intensity magnet
+∞
7.4
7
*
GBB00
NOMESCO Finland
Tracheostomy
25.2
6.8
9
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.8
6.8
24
67
WX402
NOMESCO Finland
General anaesthesia
5.7
6.6
19
42
DPA30
NOMESCO Finland
Sphenotomy
76.0
6.5
7
*
SBB10
NOMESCO Finland
Teeth copy
7.9
6.4
14
21
A07AA02
ATC
nystatin; oral
7.9
6.4
14
21
ZZQ20
NOMESCO Finland
Free microvascular graft of skin, muscle and bone
+∞
6.3
6
*
YA1CD
NOMESCO Finland
Very extensive CT examination of head and neck for dose design of radiotherapy
+∞
6.3
6
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
DPB00
NOMESCO Finland
Partial excision of frontal sinus
+∞
6.3
6
*
DNB30
NOMESCO Finland
Excision of lesion of ethmoidal sinus
+∞
6.3
6
*
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
6.2
6.1
16
31
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
29
77
4.36
10.29
2.2
2.0
0.2
0.2
g/l
1.00
29
62
23
51
5.08
10.13
9.1
6.4
24.8
25.1
mmol/l
0.15
23
45
12
13
9.88
9.99
1.2
1.1
—
—
—
0
0
53
225
3.00
9.17
3.1
2.0
—
—
—
0
0
84
465
2.64
8.63
5.8
3.4
32.4
35.5
g/l
3.85
76
415
91
558
2.41
7.09
10.4
5.5
1.2
1.2
mmol/l
0.85
75
480
80
464
2.41
7.07
6.0
3.7
—
—
—
0
0
33
131
2.90
6.26
8.0
6.0
0.8
1.6
mmol/l
0.33
26
102
80
504
2.14
5.41
8.6
5.0
1.2
1.2
mmol/l
0.67
72
444
91
622
2.03
4.75
19.1
6.3
3.9
4.2
e9/l
0.58
84
545
23
91
2.77
4.35
8.6
4.5
1.3
1.6
mmol/l
0.66
23
84
7
6
12.10
4.31
5.9
8.2
—
—
—
0
0
93
1175
0.52
3.97
4.4
4.7
4.7
4.5
mmol/l
0.85
86
1076
10
24
4.37
3.94
1.7
1.3
—
—
—
0
0
93
1167
0.53
3.72
4.5
4.6
1.4
1.4
mmol/l
0.07
85
1063
97
1199
0.54
3.62
4.8
5.2
2.8
2.6
mmol/l
0.44
88
1091
93
1162
0.54
3.56
5.6
4.7
6.0
6.1
mmol/l
0.22
82
1043
90
1126
0.56
3.30
4.3
4.2
1.3
1.3
mmol/l
0.30
80
1021
92
683
1.78
3.29
7.2
4.1
7.0
6.9
mmol/l
0.27
87
630
5
5
10.25
3.00
2.2
1.6
16.7
24.7
ug/l
—
5
5
5
5
10.25
3.00
1.8
1.0
—
—
—
0
0
11
35
3.30
2.99
1.3
4.3
—
—
—
0
0
57
377
1.78
2.96
2.4
2.8
—
—
—
0
0
17
72
2.52
2.83
1.2
1.5
—
—
—
0
0
8
18
4.61
2.83
6.5
2.3
30.5
9.7
u/ml
—
8
12
8
18
4.61
2.83
1.5
1.2
—
—
—
0
0
92
1120
0.60
2.66
6.2
6.4
40.7
40.9
mmol/mol
0.06
82
1029
5
7
7.32
2.56
1.8
1.7
2.2
3.3
mg/l
—
5
7
5
7
7.32
2.56
1.6
1.1
—
—
—
0
0
7
19
3.80
2.17
1.3
1.3
—
—
—
0
0
22
118
2.00
2.14
5.1
3.3
—
—
—
0
0
5
10
5.12
2.08
1.4
1.1
—
—
—
0
0
5
10
5.12
2.08
1.4
1.1
—
—
—
0
0
5
10
5.12
2.08
1.4
1.1
—
—
—
0
0
5
10
5.12
2.08
1.4
1.1
—
—
—
0
0
5
10
5.12
2.08
1.4
1.1
—
—
—
0
0
5
10
5.12
2.08
1.4
1.1
—
—
—
0
0
11
44
2.61
2.06
1.1
1.0
—
—
—
0
0
6
15
4.11
2.06
1.0
1.0
—
—
—
0
0
6
16
3.85
1.95
1.0
1.1
—
—
—
0
0
6
16
3.85
1.95
2.3
2.5
205.0
186.5
%
—
6
16
8
29
2.85
1.81
5.3
1.2
62.5
31.1
mg/l
—
8
24
5
13
3.93
1.72
2.8
1.3
—
—
—
0
0
7
25
2.88
1.67
1.6
1.2
—
—
—
0
0
42
295
1.57
1.65
2.3
2.6
0.3
0.5
e6/l
0.40
32
215
5
14
3.65
1.62
1.0
1.1
—
—
—
0
0
8
32
2.57
1.62
1.6
1.3
4649.1
3848.0
e6/l
—
8
25
8
32
2.57
1.62
1.6
1.2
68.0
5.9
e6/l
—
8
25
5
16
3.19
1.45
1.6
1.1
—
—
—
0
0
86
715
1.42
1.43
3.6
4.2
67.6
352.4
e6/l
—
5
11
7
29
2.47
1.41
5.9
1.2
23.6
46.8
mg/l
—
7
24
34
236
1.56
1.40
2.9
3.8
163.8
202.2
ng/l
0.09
28
184
21
316
0.62
1.26
1.3
1.7
1.2
1.4
mmol/l
0.46
14
264
10
49
2.11
1.25
3.0
4.4
26.3
24.5
mmol/l
—
10
41
27
183
1.57
1.23
2.6
1.6
—
—
—
0
0
95
1077
0.72
1.23
6.3
4.3
2.3
2.0
mu/l
0.97
84
960
5
19
2.68
1.22
3.0
1.3
—
—
—
0
0
5
20
2.54
1.16
2.8
1.3
—
—
—
0
0
20
128
1.64
1.15
2.4
1.6
—
—
—
0
0
20
129
1.63
1.12
2.4
1.7
—
—
—
0
0
13
75
1.80
1.06
2.0
1.4
—
—
—
0
0
38
287
1.42
1.04
1.9
2.0
3.0
3.1
mg/l
0.08
31
241
24
168
1.50
0.96
2.0
2.5
1.8
2.9
e6/l
0.38
16
90
7
37
1.93
0.95
2.3
1.3
—
—
—
0
0
32
239
1.42
0.94
1.7
1.6
1.2
1.1
mg/l
0.08
26
175
46
557
0.76
0.83
4.8
3.8
1.7
2.1
ug/l
1.04
41
490
54
451
1.29
0.78
2.0
2.5
195.1
126.3
ug/l
0.98
48
414
54
452
1.29
0.76
2.0
2.1
77.2
76.4
nmol/l
0.08
49
403
10
60
1.71
0.74
2.4
1.6
—
—
—
0
0
14
93
1.55
0.72
3.6
2.1
74.0
61.0
ml/min/173m2
—
6
33
5
26
1.95
0.71
1.0
1.2
—
—
—
0
0
7
42
1.70
0.69
3.6
1.5
—
—
—
0
0
11
164
0.65
0.65
13.8
7.2
—
—
—
0
0
0
20
0.00
0.61
0.0
3.8
—
41.5
—
0
6
6
39
1.56
0.53
5.7
1.1
37.2
38.7
g/l
—
6
32
6
39
1.56
0.53
5.7
1.1
11.9
10.0
g/l
—
6
34
57
644
0.82
0.53
3.0
2.5
—
—
—
0
0
48
551
0.82
0.52
4.0
3.7
0.0
0.0
estimate
0.00
11
94
80
728
1.19
0.49
3.1
2.9
56.7
49.3
u/l
0.37
75
675
5
83
0.59
0.47
1.4
1.4
—
—
—
0
0
24
294
0.79
0.46
2.9
2.6
0.7
0.8
ug/l
0.38
15
198
46
400
1.21
0.46
2.6
3.2
502.3
1706.0
ng/l
6.10
41
342
18
139
1.33
0.46
1.2
1.4
—
—
—
0
0
5
31
1.63
0.43
2.0
2.2
—
—
—
0
0
5
31
1.63
0.43
1.6
1.3
—
—
—
0
0
8
56
1.45
0.43
2.1
3.3
26.7
24.8
mmol/l
—
8
51
119
1246
0.84
0.41
32.2
14.9
79.8
82.3
umol/l
0.22
119
1246
48
540
0.84
0.41
4.0
3.7
0.0
0.0
estimate
—
9
94
48
539
0.85
0.40
5.0
5.1
0.0
0.0
estimate
—
10
95
29
246
1.22
0.37
1.6
1.8
977.3
1192.7
nmol/l
0.69
22
191
121
1157
1.17
0.36
28.8
12.8
29.3
25.2
mg/l
0.67
110
875
6
43
1.41
0.35
2.0
2.4
32.7
42.2
u/l
—
6
37
6
46
1.32
0.33
5.7
1.3
7.4
7.7
g/l
—
6
35
6
46
1.32
0.33
5.7
1.3
—
—
—
0
0
6
46
1.32
0.33
5.7
1.3
3.0
3.0
g/l
—
6
34
6
46
1.32
0.33
5.7
1.3
3.2
3.9
g/l
—
6
33
39
434
0.87
0.29
4.1
3.8
—
—
—
0
0
39
432
0.87
0.27
5.8
3.7
23.4
24.0
%
0.08
17
205
21
179
1.20
0.26
1.8
2.3
0.9
1.0
e6/l
0.03
11
101
120
1240
0.88
0.26
30.9
15.4
4.0
4.0
mmol/l
1.16
114
1190
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
39.4
—
0
6
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
48
517
0.90
0.21
3.5
4.0
35.4
114.6
ng/l
0.66
35
388
0
12
0.00
0.21
0.0
1.1
—
4.0
—
0
7
0
12
0.00
0.21
0.0
1.1
—
1.1
—
0
6
0
14
0.00
0.20
0.0
1.0
—
7.9
—
0
8
106
1096
0.91
0.20
28.4
11.5
81.9
76.4
ml/min/173m2
2.03
96
874
7
62
1.13
0.17
2.6
2.3
0.8
1.1
%
—
7
62
10
118
0.84
0.14
1.2
1.2
—
—
—
0
0
8
100
0.79
0.14
1.8
1.7
—
—
—
0
0
100
1027
0.93
0.13
27.3
13.2
36.3
40.0
%
2.07
70
668
10
86
1.17
0.11
2.0
2.9
4.6
1.5
mmol/l
—
5
59
49
507
0.95
0.07
2.0
1.9
88.1
93.8
pmol/l
0.39
30
270
29
305
0.94
0.07
4.7
3.9
0.0
0.0
estimate
0.00
11
91
30
287
1.06
0.05
1.7
1.5
15.9
20.6
nmol/l
1.03
25
249
10
91
1.11
0.04
2.2
2.8
5.1
4.9
kpa
—
10
84
87
859
1.03
0.03
5.4
3.6
14.1
15.0
pmol/l
2.23
79
779
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
24.2
—
0
5
0
6
0.00
0.00
0.0
1.0
—
2.1
—
0
6
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
2.8
—
19.3
—
0
8
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
13.9
—
0
5
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_ACCESSORY_SINUS_EXALLC – Malignant neoplasm of accessory sinuses, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).